Monograph
J07AE01 - Cholera, Inactivated, Whole Cell |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the cholera, inactivated, whole cell vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated Vibrio Cholerae of different strains of serogroup O1 and the B subunit of the cholera toxin.
Therapeutic characteristics
Dukoral is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas.
The vaccine is administered orally as two doses (three doses for children under 6), taken at least one week apart.
Metabolism and pharmacokinetics
The cholera vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Dukoral. (Last edition: March 2015).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024